Biopharmaceutical Contract Manufacturing Market Report: Trends, Forecast and Competitive Analysis
Get it in 2 to 4 weeks by ordering today
The future of the global biopharmaceutical contract manufacturing market looks promising with opportunities in commercial and clinical applications. The global biopharmaceutical contract manufacturing market is expected to grow with a CAGR of 7%-9% from 2020 to 2025. The major drivers for this market are increasing demand for biopharmaceuticals, cost and time saving benefits offered by contract services, and rising pharmaceutical industries leading to outsourcing services.
A total of XX figures / charts and XX tables are provided in this more than 150-page report to help in your business decisions. Sample figures with some insights are shown below. To learn the scope, benefits, companies researched, and other details of the global biopharmaceutical contract manufacturing market report, please download the report brochure.
In this market, biologics is the largest product of biopharmaceutical contract manufacturing, whereas process development is the largest service. Growth in various segments of the biopharmaceutical contract manufacturing market are given below:
The study includes trends and forecast for the global biopharmaceutical contract manufacturing market by product, service, therapeutic area, source, application, and region as follows:
By Product [Value ($ Million) shipment analysis for 2014 – 2025]:
BiologicsMonoclonal Antibodies (MAbs)Recombinant ProteinsVaccinesAntisense, RNAi (Ribonucleic Acid), & Molecular TherapyBiosimilars
By Service [Value ($ Million) shipment analysis for 2014 – 2025]:
Process DevelopmentDownstreamUpstreamFill & Finish OperationsAnalytical & QC (Quality Control) StudiesPackaging
By Therapeutic Area [Value ($ Million) shipment analysis for 2014 – 2025]:
Autoimmune DiseaseOncologyMetabolic DiseaseOphthalmologyCardiovascular DiseaseInfectious DiseaseNeurologyRespiratory DisorderOthers
By Source [Value ($ Million) shipment analysis for 2014 – 2025]:
MammalianNon-Mammalian
By Application [Value ($ Million) shipment analysis for 2014 – 2025]:
CommercialClinical
By Region [Value ($ Million) shipment analysis for 2014 – 2025]:
North AmericaUnited StatesCanada MexicoEuropeUnited KingdomGermanyFranceAsia PacificChinaIndiaJapanThe Rest of the WorldBrazil
Some of the biopharmaceutical contract manufacturing companies profiled in this report include Lonza, Inno Biologics, Rentschler Biotechnologie, JRS Pharma, AGC Biologics, ProBioGen, Fujifilm Diosynth Biotechnologies, Toyobo, Samsung BioLogics, and Thermo Fisher Scientific.
Lucintel forecasts that biologics will remain the largest product segment over the forecast period due to increasing stringent regulatory framework related to biologics which is forcing pharmaceutical companies to adopt for contract manufacturing services.
Within this market, process development will remain the largest service segment over the forecast period due to the presence of advanced technologies and high capital expenditure in small and medium pharmaceutical companies that are opting for contract manufacturing.
North America will remain the largest region over the forecast period due to increasing research activities related to biopharmaceutical, rising demand for biologics, and presence of major pharmaceutical companies in the region.
Features of the Global Biopharmaceutical Contract Manufacturing Market
Market Size Estimates: Global biopharmaceutical contract manufacturing market size estimation in terms of value ($M) shipment.Trend and Forecast Analysis: Market trends (2014-2019) and forecast (2020-2025) by various segments.Segmentation Analysis: Global biopharmaceutical contract manufacturing market size by various segments, such as product, service, therapeutic area, source, and application in terms of value.Regional Analysis: Global biopharmaceutical contract manufacturing market breakdown by North America, Europe, Asia Pacific, and Rest of the World.Growth Opportunities: Analysis of growth opportunities in different product, service, therapeutic area, source, application, and region for the global biopharmaceutical contract manufacturing market.Strategic Analysis: This includes M&A, new product development, and competitive landscape of the global biopharmaceutical contract manufacturing market.Analysis of competitive intensity of the industry based on Porter’s Five Forces model.
This report answers following key questions
Q.1 What are some of the most promising potential, high-growth opportunities for the global biopharmaceutical contract manufacturing market by product (biologics (monoclonal antibodies (MAbs), recombinant proteins, and vaccines), antisense, RNAi, & molecular therapy, and biosimilars), service (process development (downstream and upstream), fill & finish operations, analytical & QC studies, and packaging), therapeutic area (autoimmune disease, oncology, metabolic disease, ophthalmology, cardiovascular disease, infectious disease, neurology, respiratory disorder, and others), source (mammalian and non-mammalian), application (commercial and clinical), and region (North America, Europe, Asia Pacific, and Rest of the World)?
Q.2 Which segments will grow at a faster pace and why?
Q.3 Which region will grow at a faster pace and why?
Q.4 What are the key factors affecting market dynamics? What are the drivers and challenges of the global biopharmaceutical contract manufacturing market?
Q.5 What are the business risks and threats to the global biopharmaceutical contract manufacturing market?
Q.6 What are the emerging trends in this biopharmaceutical contract manufacturing market and the reasons behind them?
Q.7 What are some changing demands of customers in this biopharmaceutical contract manufacturing market?
Q.8 What are the new developments in this biopharmaceutical contract manufacturing market? Which companies are leading these developments?
Q.9 Who are the major players in this biopharmaceutical contract manufacturing market? What strategic initiatives are being implemented by key players for business growth?
Q.10 What are some of the competitive products and processes in this biopharmaceutical contract manufacturing market, and how big of a threat do they pose for loss of market share via material or product substitution?
Q.11 What M&A activities did take place in the last five years in the global biopharmaceutical contract manufacturing market?
Report Scope
Key Features Description
Base Year for Estimation 2019
Trend Period
(Actual Estimates) 2014-2019
Forecast Period 2020-2025
Pages More than 150
Market Representation / Units Revenue in US $ Million
Report Coverage Market Trends & Forecasts, Competitor Analysis, New Product Development, Company Expansion, Merger, Acquisitions & Joint Venture, and Company Profiling
Market Segments Product (Biologics, Antisense, RNAi, & Molecular Therapy, and Biosimilars), Service (Process Development (Downstream and Upstream), Fill & Finish Operations, Analytical & QC Studies, and Packaging), Therapeutic Area (Autoimmune Disease, Oncology, Metabolic Disease, Ophthalmology, Cardiovascular Disease, Infectious Disease, Neurology, Respiratory Disorder, and Others), Source (Mammalian and Non-Mammalian), and Application (Commercial and Clinical)
Regional Scope North America (USA, Mexico, and Canada), Europe (United Kingdom, Germany, and France), Asia (China, India, and Japan), and ROW (Brazil)
Customization 10% Customization without Any Additional Cost
The future of the global biopharmaceutical contract manufacturing market looks promising with opportunities in commercial and clinical applications. The global biopharmaceutical contract manufacturing market is expected to grow with a CAGR of 7%-9% from 2020 to 2025. The major drivers for this market are increasing demand for biopharmaceuticals, cost and time saving benefits offered by contract services, and rising pharmaceutical industries leading to outsourcing services.
A total of XX figures / charts and XX tables are provided in this more than 150-page report to help in your business decisions. Sample figures with some insights are shown below. To learn the scope, benefits, companies researched, and other details of the global biopharmaceutical contract manufacturing market report, please download the report brochure.
In this market, biologics is the largest product of biopharmaceutical contract manufacturing, whereas process development is the largest service. Growth in various segments of the biopharmaceutical contract manufacturing market are given below:
The study includes trends and forecast for the global biopharmaceutical contract manufacturing market by product, service, therapeutic area, source, application, and region as follows:
By Product [Value ($ Million) shipment analysis for 2014 – 2025]:
BiologicsMonoclonal Antibodies (MAbs)Recombinant ProteinsVaccinesAntisense, RNAi (Ribonucleic Acid), & Molecular TherapyBiosimilars
By Service [Value ($ Million) shipment analysis for 2014 – 2025]:
Process DevelopmentDownstreamUpstreamFill & Finish OperationsAnalytical & QC (Quality Control) StudiesPackaging
By Therapeutic Area [Value ($ Million) shipment analysis for 2014 – 2025]:
Autoimmune DiseaseOncologyMetabolic DiseaseOphthalmologyCardiovascular DiseaseInfectious DiseaseNeurologyRespiratory DisorderOthers
By Source [Value ($ Million) shipment analysis for 2014 – 2025]:
MammalianNon-Mammalian
By Application [Value ($ Million) shipment analysis for 2014 – 2025]:
CommercialClinical
By Region [Value ($ Million) shipment analysis for 2014 – 2025]:
North AmericaUnited StatesCanada MexicoEuropeUnited KingdomGermanyFranceAsia PacificChinaIndiaJapanThe Rest of the WorldBrazil
Some of the biopharmaceutical contract manufacturing companies profiled in this report include Lonza, Inno Biologics, Rentschler Biotechnologie, JRS Pharma, AGC Biologics, ProBioGen, Fujifilm Diosynth Biotechnologies, Toyobo, Samsung BioLogics, and Thermo Fisher Scientific.
Lucintel forecasts that biologics will remain the largest product segment over the forecast period due to increasing stringent regulatory framework related to biologics which is forcing pharmaceutical companies to adopt for contract manufacturing services.
Within this market, process development will remain the largest service segment over the forecast period due to the presence of advanced technologies and high capital expenditure in small and medium pharmaceutical companies that are opting for contract manufacturing.
North America will remain the largest region over the forecast period due to increasing research activities related to biopharmaceutical, rising demand for biologics, and presence of major pharmaceutical companies in the region.
Features of the Global Biopharmaceutical Contract Manufacturing Market
Market Size Estimates: Global biopharmaceutical contract manufacturing market size estimation in terms of value ($M) shipment.Trend and Forecast Analysis: Market trends (2014-2019) and forecast (2020-2025) by various segments.Segmentation Analysis: Global biopharmaceutical contract manufacturing market size by various segments, such as product, service, therapeutic area, source, and application in terms of value.Regional Analysis: Global biopharmaceutical contract manufacturing market breakdown by North America, Europe, Asia Pacific, and Rest of the World.Growth Opportunities: Analysis of growth opportunities in different product, service, therapeutic area, source, application, and region for the global biopharmaceutical contract manufacturing market.Strategic Analysis: This includes M&A, new product development, and competitive landscape of the global biopharmaceutical contract manufacturing market.Analysis of competitive intensity of the industry based on Porter’s Five Forces model.
This report answers following key questions
Q.1 What are some of the most promising potential, high-growth opportunities for the global biopharmaceutical contract manufacturing market by product (biologics (monoclonal antibodies (MAbs), recombinant proteins, and vaccines), antisense, RNAi, & molecular therapy, and biosimilars), service (process development (downstream and upstream), fill & finish operations, analytical & QC studies, and packaging), therapeutic area (autoimmune disease, oncology, metabolic disease, ophthalmology, cardiovascular disease, infectious disease, neurology, respiratory disorder, and others), source (mammalian and non-mammalian), application (commercial and clinical), and region (North America, Europe, Asia Pacific, and Rest of the World)?
Q.2 Which segments will grow at a faster pace and why?
Q.3 Which region will grow at a faster pace and why?
Q.4 What are the key factors affecting market dynamics? What are the drivers and challenges of the global biopharmaceutical contract manufacturing market?
Q.5 What are the business risks and threats to the global biopharmaceutical contract manufacturing market?
Q.6 What are the emerging trends in this biopharmaceutical contract manufacturing market and the reasons behind them?
Q.7 What are some changing demands of customers in this biopharmaceutical contract manufacturing market?
Q.8 What are the new developments in this biopharmaceutical contract manufacturing market? Which companies are leading these developments?
Q.9 Who are the major players in this biopharmaceutical contract manufacturing market? What strategic initiatives are being implemented by key players for business growth?
Q.10 What are some of the competitive products and processes in this biopharmaceutical contract manufacturing market, and how big of a threat do they pose for loss of market share via material or product substitution?
Q.11 What M&A activities did take place in the last five years in the global biopharmaceutical contract manufacturing market?
Report Scope
Key Features Description
Base Year for Estimation 2019
Trend Period
(Actual Estimates) 2014-2019
Forecast Period 2020-2025
Pages More than 150
Market Representation / Units Revenue in US $ Million
Report Coverage Market Trends & Forecasts, Competitor Analysis, New Product Development, Company Expansion, Merger, Acquisitions & Joint Venture, and Company Profiling
Market Segments Product (Biologics, Antisense, RNAi, & Molecular Therapy, and Biosimilars), Service (Process Development (Downstream and Upstream), Fill & Finish Operations, Analytical & QC Studies, and Packaging), Therapeutic Area (Autoimmune Disease, Oncology, Metabolic Disease, Ophthalmology, Cardiovascular Disease, Infectious Disease, Neurology, Respiratory Disorder, and Others), Source (Mammalian and Non-Mammalian), and Application (Commercial and Clinical)
Regional Scope North America (USA, Mexico, and Canada), Europe (United Kingdom, Germany, and France), Asia (China, India, and Japan), and ROW (Brazil)
Customization 10% Customization without Any Additional Cost
1. EXECUTIVE SUMMARY
2. MARKET BACKGROUND AND CLASSIFICATIONS
2.1: Introduction, Background, and Classifications
2.2: Supply Chain
2.3: Industry Drivers and Challenges
3. MARKET TRENDS AND FORECAST ANALYSIS FROM 2014 T 2025
3.1: Macroeconomic Trends and Forecast
3.2: Global Biopharmaceutical Contract Manufacturing Market Trends and Forecast
3.3: Global Biopharmaceutical Contract Manufacturing Market by Product
3.3.1: Biologics
3.3.1.1: Monoclonal Antibodies (MAbs)
3.3.1.2: Recombinant Proteins
3.3.1.3: Vaccines
3.3.2: Antisense, RNAi, & Molecular Therapy
3.3.3: Biosimilars
3.4: Global Biopharmaceutical Contract Manufacturing Market by Service
3.4.1: Process Development
3.4.1.1: Downstream
3.4.1.2: Upstream
3.4.2: Fill & Finish Operations
3.4.3: Analytical & QC Studies
3.4.4: Packaging
3.5: Global Biopharmaceutical Contract Manufacturing Market by Therapeutic Area
3.5.1: Autoimmune Disease
3.5.2: Oncology
3.5.3: Metabolic Disease
3.5.4: Opthalmology
3.5.5: Cardiovascular Disease
3.5.6: Infectious Disease
3.5.7: Neurology
3.5.8: Respiratory Disorder
3.5.9: Others
3.6: Global Biopharmaceutical Contract Manufacturing Market by Source
3.6.1: Mammalian
3.6.2: Non-Mammalian
3.7: Global Biopharmaceutical Contract Manufacturing Market by Application
3.7.1: Commercial
3.7.2: Clinical
4. MARKET TRENDS AND FORECAST ANALYSIS BY REGION
4.1: Global Biopharmaceutical Contract Manufacturing Market by Region
4.2: North American Biopharmaceutical Contract Manufacturing Market
4.2.1: Market by Product: Biologics (Monoclonal Antibodies (MAbs), Recombinant Proteins, and Vaccines), Antisense, RNAi, & Molecular Therapy, and Biosimilars
4.2.2: Market by Service: Process Development (Downstream and Upstream), Fill & Finish Operations, Analytical & QC Studies, and Packaging
4.2.3: Market by Therapeutic Area: Autoimmune Disease, Oncology, Metabolic Disease, Opthalmology, Cardiovascular Disease, Infectious Disease, Neurology, Respiratory Disorder, and Others
4.2.4: Market by Source: Mammalian and Non-Mammalian
4.2.5: Market by Application: Commercial and Clinical
4.2.6: The United States Biopharmaceutical Contract Manufacturing Market
4.2.7: The Canadian Biopharmaceutical Contract Manufacturing Market
4.2.8: The Mexican Biopharmaceutical Contract Manufacturing Market
4.3: European Biopharmaceutical Contract Manufacturing Market
4.3.1: Market by Product: Biologics (Monoclonal Antibodies (MAbs), Recombinant Proteins, and Vaccines), Antisense, RNAi, & Molecular Therapy, and Biosimilars
4.3.2: Market by Service: Process Development (Downstream and Upstream), Fill & Finish Operations, Analytical & QC Studies, and Packaging
4.3.3: Market by Therapeutic Area: Autoimmune Disease, Oncology, Metabolic Disease, Opthalmology, Cardiovascular Disease, Infectious Disease, Neurology, Respiratory Disorder, and Others
4.3.4: Market by Source: Mammalian and Non-Mammalian
4.3.5: Market by Application: Commercial and Clinical
4.3.6: The Biopharmaceutical Contract Manufacturing Market of United Kingdom
4.3.7: The German Biopharmaceutical Contract Manufacturing Market
4.3.8: The French Biopharmaceutical Contract Manufacturing Market
4.4: APAC Biopharmaceutical Contract Manufacturing Market
4.4.1: Market by Product: Biologics (Monoclonal Antibodies (MAbs), Recombinant Proteins, and Vaccines), Antisense, RNAi, & Molecular Therapy, and Biosimilars
4.4.2: Market by Service: Process Development (Downstream and Upstream), Fill & Finish Operations, Analytical & QC Studies, and Packaging
4.4.3: Market by Therapeutic Area: Autoimmune Disease, Oncology, Metabolic Disease, Opthalmology, Cardiovascular Disease, Infectious Disease, Neurology, Respiratory Disorder, and Others
4.4.4: Market by Source: Mammalian and Non-Mammalian
4.4.5: Market by Application: Commercial and Clinical
4.4.6: The Chinese Biopharmaceutical Contract Manufacturing Market
4.4.7: The Indian Biopharmaceutical Contract Manufacturing Market
4.4.8: The Japanese Biopharmaceutical Contract Manufacturing Market
4.5: ROW Biopharmaceutical Contract Manufacturing Market
4.5.1: Market by Product: Biologics (Monoclonal Antibodies (MAbs), Recombinant Proteins, and Vaccines), Antisense, RNAi, & Molecular Therapy, and Biosimilars
4.5.2: Market by Service: Process Development (Downstream and Upstream), Fill & Finish Operations, Analytical & QC Studies, and Packaging
4.5.3: Market by Therapeutic Area: Autoimmune Disease, Oncology, Metabolic Disease, Opthalmology, Cardiovascular Disease, Infectious Disease, Neurology, Respiratory Disorder, and Others
4.5.4: Market by Source: Mammalian and Non-Mammalian
4.5.5: Market by Application: Commercial and Clinical
4.5.6: Brazilian Biopharmaceutical Contract Manufacturing Market
5. COMPETITOR ANALYSIS
5.1: Market Share Analysis
5.2: Product Portfoli Analysis
5.3: Operational Integration
5.4: Geographical Reach
5.5: Porter’s Five Forces Analysis
6. COST STRUCTURE ANALYSIS
6.1: Cost of Goods Sold
6.2: SG&A
6.3: EBITDA Margin
7. GROWTH OPPORTUNITIES AND STRATEGIC ANALYSIS
7.1: Growth Opportunity Analysis
7.1.1: Growth Opportunities for the Global Biopharmaceutical Contract Manufacturing Market by Product
7.1.2: Growth Opportunities for the Global Biopharmaceutical Contract Manufacturing Market by Service
7.1.3: Growth Opportunities for the Global Biopharmaceutical Contract Manufacturing Market by Therapeutic Area
7.1.4: Growth Opportunities for the Global Biopharmaceutical Contract Manufacturing Market by Source
7.1.5: Growth Opportunities for the Global Biopharmaceutical Contract Manufacturing Market by Application
7.1.6: Growth Opportunities for the Global Biopharmaceutical Contract Manufacturing Market by Region
7.2: Emerging Trends in the Global Biopharmaceutical Contract Manufacturing Market
7.3: Strategic Analysis
7.3.1: New Product Development
7.3.2: Capacity Expansion of the Global Biopharmaceutical Contract Manufacturing Market
7.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Biopharmaceutical Contract Manufacturing Market
7.3.4: Certification and Licensing
8. COMPANY PROFILES OF LEADING PLAYERS
8.1: Lonza Group Ltd.
8.2: Inn Biologics Sdn Bhd
8.3: Rentschler Biotechnologie GmbH
8.4: JRS Pharma
8.5: AGC Biologics
8.6: ProBioGen
8.7: Fujifilm Diosynth Biotechnologies U.S.A., Inc.
8.8: Toyob Co., Ltd.
8.9: Samsung BioLogics
8.10: Therm Fisher Scientific, Inc.
2. MARKET BACKGROUND AND CLASSIFICATIONS
2.1: Introduction, Background, and Classifications
2.2: Supply Chain
2.3: Industry Drivers and Challenges
3. MARKET TRENDS AND FORECAST ANALYSIS FROM 2014 T 2025
3.1: Macroeconomic Trends and Forecast
3.2: Global Biopharmaceutical Contract Manufacturing Market Trends and Forecast
3.3: Global Biopharmaceutical Contract Manufacturing Market by Product
3.3.1: Biologics
3.3.1.1: Monoclonal Antibodies (MAbs)
3.3.1.2: Recombinant Proteins
3.3.1.3: Vaccines
3.3.2: Antisense, RNAi, & Molecular Therapy
3.3.3: Biosimilars
3.4: Global Biopharmaceutical Contract Manufacturing Market by Service
3.4.1: Process Development
3.4.1.1: Downstream
3.4.1.2: Upstream
3.4.2: Fill & Finish Operations
3.4.3: Analytical & QC Studies
3.4.4: Packaging
3.5: Global Biopharmaceutical Contract Manufacturing Market by Therapeutic Area
3.5.1: Autoimmune Disease
3.5.2: Oncology
3.5.3: Metabolic Disease
3.5.4: Opthalmology
3.5.5: Cardiovascular Disease
3.5.6: Infectious Disease
3.5.7: Neurology
3.5.8: Respiratory Disorder
3.5.9: Others
3.6: Global Biopharmaceutical Contract Manufacturing Market by Source
3.6.1: Mammalian
3.6.2: Non-Mammalian
3.7: Global Biopharmaceutical Contract Manufacturing Market by Application
3.7.1: Commercial
3.7.2: Clinical
4. MARKET TRENDS AND FORECAST ANALYSIS BY REGION
4.1: Global Biopharmaceutical Contract Manufacturing Market by Region
4.2: North American Biopharmaceutical Contract Manufacturing Market
4.2.1: Market by Product: Biologics (Monoclonal Antibodies (MAbs), Recombinant Proteins, and Vaccines), Antisense, RNAi, & Molecular Therapy, and Biosimilars
4.2.2: Market by Service: Process Development (Downstream and Upstream), Fill & Finish Operations, Analytical & QC Studies, and Packaging
4.2.3: Market by Therapeutic Area: Autoimmune Disease, Oncology, Metabolic Disease, Opthalmology, Cardiovascular Disease, Infectious Disease, Neurology, Respiratory Disorder, and Others
4.2.4: Market by Source: Mammalian and Non-Mammalian
4.2.5: Market by Application: Commercial and Clinical
4.2.6: The United States Biopharmaceutical Contract Manufacturing Market
4.2.7: The Canadian Biopharmaceutical Contract Manufacturing Market
4.2.8: The Mexican Biopharmaceutical Contract Manufacturing Market
4.3: European Biopharmaceutical Contract Manufacturing Market
4.3.1: Market by Product: Biologics (Monoclonal Antibodies (MAbs), Recombinant Proteins, and Vaccines), Antisense, RNAi, & Molecular Therapy, and Biosimilars
4.3.2: Market by Service: Process Development (Downstream and Upstream), Fill & Finish Operations, Analytical & QC Studies, and Packaging
4.3.3: Market by Therapeutic Area: Autoimmune Disease, Oncology, Metabolic Disease, Opthalmology, Cardiovascular Disease, Infectious Disease, Neurology, Respiratory Disorder, and Others
4.3.4: Market by Source: Mammalian and Non-Mammalian
4.3.5: Market by Application: Commercial and Clinical
4.3.6: The Biopharmaceutical Contract Manufacturing Market of United Kingdom
4.3.7: The German Biopharmaceutical Contract Manufacturing Market
4.3.8: The French Biopharmaceutical Contract Manufacturing Market
4.4: APAC Biopharmaceutical Contract Manufacturing Market
4.4.1: Market by Product: Biologics (Monoclonal Antibodies (MAbs), Recombinant Proteins, and Vaccines), Antisense, RNAi, & Molecular Therapy, and Biosimilars
4.4.2: Market by Service: Process Development (Downstream and Upstream), Fill & Finish Operations, Analytical & QC Studies, and Packaging
4.4.3: Market by Therapeutic Area: Autoimmune Disease, Oncology, Metabolic Disease, Opthalmology, Cardiovascular Disease, Infectious Disease, Neurology, Respiratory Disorder, and Others
4.4.4: Market by Source: Mammalian and Non-Mammalian
4.4.5: Market by Application: Commercial and Clinical
4.4.6: The Chinese Biopharmaceutical Contract Manufacturing Market
4.4.7: The Indian Biopharmaceutical Contract Manufacturing Market
4.4.8: The Japanese Biopharmaceutical Contract Manufacturing Market
4.5: ROW Biopharmaceutical Contract Manufacturing Market
4.5.1: Market by Product: Biologics (Monoclonal Antibodies (MAbs), Recombinant Proteins, and Vaccines), Antisense, RNAi, & Molecular Therapy, and Biosimilars
4.5.2: Market by Service: Process Development (Downstream and Upstream), Fill & Finish Operations, Analytical & QC Studies, and Packaging
4.5.3: Market by Therapeutic Area: Autoimmune Disease, Oncology, Metabolic Disease, Opthalmology, Cardiovascular Disease, Infectious Disease, Neurology, Respiratory Disorder, and Others
4.5.4: Market by Source: Mammalian and Non-Mammalian
4.5.5: Market by Application: Commercial and Clinical
4.5.6: Brazilian Biopharmaceutical Contract Manufacturing Market
5. COMPETITOR ANALYSIS
5.1: Market Share Analysis
5.2: Product Portfoli Analysis
5.3: Operational Integration
5.4: Geographical Reach
5.5: Porter’s Five Forces Analysis
6. COST STRUCTURE ANALYSIS
6.1: Cost of Goods Sold
6.2: SG&A
6.3: EBITDA Margin
7. GROWTH OPPORTUNITIES AND STRATEGIC ANALYSIS
7.1: Growth Opportunity Analysis
7.1.1: Growth Opportunities for the Global Biopharmaceutical Contract Manufacturing Market by Product
7.1.2: Growth Opportunities for the Global Biopharmaceutical Contract Manufacturing Market by Service
7.1.3: Growth Opportunities for the Global Biopharmaceutical Contract Manufacturing Market by Therapeutic Area
7.1.4: Growth Opportunities for the Global Biopharmaceutical Contract Manufacturing Market by Source
7.1.5: Growth Opportunities for the Global Biopharmaceutical Contract Manufacturing Market by Application
7.1.6: Growth Opportunities for the Global Biopharmaceutical Contract Manufacturing Market by Region
7.2: Emerging Trends in the Global Biopharmaceutical Contract Manufacturing Market
7.3: Strategic Analysis
7.3.1: New Product Development
7.3.2: Capacity Expansion of the Global Biopharmaceutical Contract Manufacturing Market
7.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Biopharmaceutical Contract Manufacturing Market
7.3.4: Certification and Licensing
8. COMPANY PROFILES OF LEADING PLAYERS
8.1: Lonza Group Ltd.
8.2: Inn Biologics Sdn Bhd
8.3: Rentschler Biotechnologie GmbH
8.4: JRS Pharma
8.5: AGC Biologics
8.6: ProBioGen
8.7: Fujifilm Diosynth Biotechnologies U.S.A., Inc.
8.8: Toyob Co., Ltd.
8.9: Samsung BioLogics
8.10: Therm Fisher Scientific, Inc.
